Pharma giant Novo Nordisk announced that it is collaborating with WeightWatchers to offer Wegovy through NovoCare Pharmacy, effective July 1. Through the partnership, WeightWatchers' telehealth ...

Novo Nordisk NOVO.B -0.28% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date.

Novo Nordisk is under fire over a Spanish obesity awareness campaign. After the campaign stirred up controversy, the Spanish ministry of health wrote to the drugmaker about a possible violation of ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.

Hims & Hers stock fell 35% after Novo Nordisk ended their partnership on Monday. Novo Nordisk stopped the deal because Hims sold a cheaper version of Wegovy.

Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds Novo Nordisk and Hims & Hers just announced a partnership in April.

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.